Inclusion of diverse and medically underserved populations in the design and implementation of the premmplus patient-facing APP
Active Project Grant Awarded Last action
- Award ID
- R01CA292900
- Recipient
-
Dana-Farber Cancer Institute, Inc. UEI DPMGH9MG1X67
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,389,257
Award facts
- Assistance listing
- 93.393 Cancer Cause and Prevention Research
- Completion date 43% complete
- Place of performance
- Boston, MA 02215, USA
Award details come from USAspending.gov.
Description
- Abstract
- The increasing use of genetic testing and the development of syndrome-specific risk models has transformed hereditary cancer risk assessment. We were funded under R01CA132829 awards (4/1/2008-PRESENT) to DE- velop the PREMM1,2,6, and PREMM5, risk assessment models, which use family history to identify individuals with a clinically significant risk of carrying a germline pathogenic variant (PV) associated with lynch syndrome (LS). These models are recommended by national guidelines and widely used. We subsequently developed the premmplus model to keep pace with the changing practice of multigene panel testing for several heredi- tary cancer syndromes. Premmplus predicts risk of carrying a PV in one of 19 genes implicated in 18 heredi- tary cancers and was developed and validated from patient data of approximately 30,000 patients. Published in journal of clinical oncology this year, the model demonstrated greater than 90% sensitivity and negative pre- dictive values. Despite progress in the development of better methodologies for risk assessment and the fact that national guidelines recommend familial cancer risk assessment in primary care, these assessments are rarely performed, leaving many patients with hereditary cancer syndromes unidentified. Patients from marginal- ized backgrounds are even less likely to receive guideline-directed risk assessment and genetic testing, result- ING in cancer health inequities. Providers report multiple barriers to conducting risk assessment, including time in the clinical appointment, knowledge of risk criteria, and limited numbers of genetic counselors. Risk assess- ment that can provide comprehensive and systemic identification of inherited cancer risk, along with clear clini- CAL decision support for providers is a critical unmet need. Further, this risk assessment must be integrable into clinical workflows as well as scalable and sustainable in diverse clinical settings. To increase access to COM- prehensive cancer risk assessment, we have developed a patient-facing premmplus electronic health applica- tion (APP). We propose to use an implementation science approach to design and evaluate scalable and sustainable implementation strategies; we will conduct our implementation science study in 5500 patients from 3 diverse community health settings, each of which serves a unique medically marginalized popula- tion. We will refine the APP and implementation strategies - tailoring them to the unique needs of each site - in a year-long pre-implementation phase. We will use mixed-methods approaches to evaluate the outcomes of this study against multiple strong theoretical frameworks. To accomplish these goals, we propose the following specific aims: 1) evaluate a patient-facing premmplus APP in diverse community health settings in a large multi-center implementation study, 2) evaluate barriers and facilitators to systematic hereditary cancer risk as- sessment and refine long-term strategies for scalability and sustainability, and 3) build EHR-compatible appli- cations and evaluate their ability to further increase sustainability and scalability. This project will produce an approach to hereditary cancer multigene testing that is scalable and sustainable in many healthcare systems.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $2,166,507 | |
| Amendment | $0 | |
| Amendment | $689,204 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $766,773 | |
| Original award | $766,773 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Vanderbilt University Medical Center | $40,511 | |
| Kaiser Foundation Hospitals | $66,936 | |
| Denver Health And Hospital Authority | $58,304 | |
| Kaiser Foundation Hospitals | $66,741 | |
| Kalispell Regional Medical Center Inc. | $46,817 | |
| Vanderbilt University Medical Center | $40,511 | |
| Denver Health And Hospital Authority | $58,474 |
Quick answers
Who received award R01CA292900?
R01CA292900 was awarded to Dana-Farber Cancer Institute, Inc. by National Cancer Institute (National Institutes of Health) on September 4, 2024.
How much is award R01CA292900 worth?
$4,389,257 has been obligated on R01CA292900.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award